Day 3 :
Keynote Forum
Samer Ellahham
Cleveland Clinic, USA and Cleveland Clinic Abu Dhabi, UAE
Keynote: Echocardiography of mitral valve made simple
Time : 10:00-11:00
Biography:
Samer Ellahham has served as Chief Quality Officer for SKMC since 2009. Dr. Ellahham is a Board-certified internist, cardiologist, and vascular medicine senior consultant and continues to care for patients. Ellahham did his fellowship in Cardiology at the Medical College of Virginia (MCV) in USA. He is a fellow of the American College of Cardiology and a key member in Heart Failure and Transplant, Adult Congenital and Pediatric Cardiology, Cardio-oncology and Peripheral Vascular Disease Sections. He is the Eminent Editor of The Journal of Cardiology & Cardiovascular Therapy. He is also a reviewer for several peer-reviewed journals, including Joint Commission Journal on Quality and Patient Safety, etc. He received several research awards including the DuPont Pharmaceuticals Research Award, ACCP 58th Annual Scientific Assembly, Young Investigator Award; the Alfred Soffer Research Award and many.He serves on a number of US and international committees and advisory bodies. He is the Middle East Regional Chair of the Patient Safety Movement Foundation.Dr. Ellahham is Certified Professional in Healthcare Quality (CPHQ) by The National Association for Healthcare Quality (NAHQ). He is certified in Medical Quality (CMQ) by The American Board of Medical Quality (ABMQ). He is currently working as Cleveland Clinic Caregiver and cardiology consultant in Cleveland Clinic Abu Dhabi, in Abu Dhabi, UAE.
Abstract:
The mitral valve apparatus is a complex system. Echocardiography is the primary diagnostic modality for evaluation of mitral valve structure and function. Mitral valve obstruction is caused most commonly by rheumatic mitral stenosis. Less common causes include tumors, mitral annular calcification, carcinoid heart disease, and congenital disorders. In the presence of characteristic valvular and subvalvular structural changes, severe mitral stenosis is associated with a mean transmitral gradient greater than 10 mmHg, pulmonary artery systolic pressure greater than 50 mmHg, and a mitral valve area less than 1.0 cm2. In patients with rheumatic mitral stenosis who are potential candidates for percutaneous mitral balloon valvotomy, echocardiography is key to evaluate the likelihood of procedural success. Echocardiography enables quantification of the severity of mitral regurgitation and identification of causes including mitral valve prolapse, flail mitral leaflet, endocarditis, ischemic heart disease, functional regurgitation caused by a cardiomyopathy, and rheumatic mitral disease. New modalities of echocardiography add more value in the overall assessment and treatment of mitral valvular heart disease.
- Angiography and Interventional Cardiology | Vascular Surgery | Cardiovascular Medicine | Arrhythmias | Cardio-Oncology | Clinical Cardiology | Cardiac Surgery
Location: Akdeniz 3
Session Introduction
Taner Seker
Osmaniye State Hospital, Turkey
Title: Late PCI and CABG for secondary intervention are associated with decreased MACE in patients with multivessel disease after successful primary PCI
Time : 12:00 - 12:30
Biography:
Abstract:
Background: Most patients with ST elevation myocardial infarction (STEMI) have critical multivessel disease that requiring a second intervention. The optimal timing of secondary intervention is not clear. In this study, we aimed to investigate MACE rate regarding the type of secondary procedure to non-infarct related critical lesions in patients with STEMI and critical multi vessel disease.
Methods: A total of 212 consecutive patients with STEMI and critical multi vessel disease had been included in our study. Patients were divided into two groups according to occurrence of MACE. Primary PCI data were collected. Pre and post intervention coronary blood flow and complications were recorded. MACE data of patients were evaluated before discharge, after 3 and 9 months.
Results: A second coronary angiography was performed 132 (62.3%) of STEMI patients in 90 day after primer PCI. The non- infarct related lesions in 26 of 132 patients who underwent second coronary angiography were evaluated non-critically and decided to follow with medical treatment. Secondary PCI was performed 89 of 132 and 17 of 132 patients underwent CABG operation. Patients were divided into two groups according to MACE occurrence. Mean time interval to PCI was significantly lower in patients with MACE (p=0.028). EF (p=0.59) and rate of patients who underwent CABG (p=0.108) were lower, syntax score (p=0.55) and CAD history (p=0.056) were higher in patients with MACE; but there was no statistical significance. The cut-off value of time interval to PCI obtained by ROC curve analysis was 16,5 days for prediction of MACE in 9 months (sensitivity: 75.0%, specificity: 69.2%). The area under the curve (AUC) was 0.680 (p=0.039) (Figure-1).
Conclusion: Late PCI or CABG can be thought to be the optimal strategy for patients with STEMI and multivessel disease.
Abigali Vowels
Community Regional Medical Center, USA
Title: PHQ – 9 Scores does not predict driveline site infection in patients with a left ventricular assist device
Time : 12:30-13:00
Biography:
Abstract:
Agata W Dżeljilji
National Tuberculosis and Lung Diseases Research Institute, Poland
Title: Alpha-1 antitrypsin deficiency (AATD) as a risk factor of aortic aneurysm- Is it still actual?
Time : 13:00-13:30
Biography:
Abstract:
Mansoor Ahmed
J B Gupta Hospital Bhiwani, India
Title: Effect of Intravascular metoprolol administration to prevent fatal arrhythmias in patients of STEMI undergoing primary percutaneous coronary angioplasty
Time : 14:30-15:00
Biography:
Abstract:
Pervaiz Chaudry
Diplomate American Boards of Cardiothoracic Surgery, USA
Title: Initial experience of minimally invasive concomitant aortic & mitral valve replacement / repair at a tertiary care cardiac centre of a developing country
Time : 15:00-15:30
Biography:
Abstract:
- Heart Disease and Failure | Heart Device | Pediatric and Geriatric Cardiology | Case Reports In Cardiology | Neuro-Cardiology | Hypertension | Heart Device | Cardiology-Future Medicine
Location: Akdeniz 3
Session Introduction
Waheib A Bamatraf
Saud Al-Babtain Cardiac Center, Saudi Arabia
Title: Case report of Ivabradine use post acute MI complicated by cardiogenic shock and review of literature
Time : 11:30-12:00
Biography:
Abstract:
Sekib Sokolovic
University Clinical Center Sarajevo, Bosnia and Herzegovina
Title: Ajmalin is a drug of choice in paroxisimal tachycardia
Time : 12:00-12:30
Biography:
Abstract:
Abdullah Orhan Demirtas
Health Sciences University, Turkey
Title: A new predictor in patients with cardiac implantable electronic device for iatrogenic pneumothorax: The pneumothorax index
Time : 12:30-13:00
Biography:
Abstract:
Armin Attar
Shiraz University of Medical Sciences, Iran
Title: Cardiovascular risk based intensive blood pressure reduction
Time : 14:00-14:30
Biography:
Abstract:
Sawsan Al Yousef
CRESENT, King Fahad Medical City, Saudi Arabia
Title: Medical simulation training and heart rhythm identification
Time : 14:30-15:00
Biography:
Abstract:
- Workshop
Location: Akdeniz 3
Session Introduction
Marc Ghannoum
University of Montreal, Canada
Title: Hemodialysis and hemoperfusion for treatment of poisoning to cardio toxic drugs
Biography:
Abstract:
Historically, the clinical application of extracorporeal treatments (ECTRs), such as hemodialysis or hemoperfusion, was first intended for poisoned patients. With time, ECTRs were used almost indiscriminately to facilitate the elimination of many poisons, albeit with uncertain clinical benefit. To determine the precise role of ECTRs in poisoning situations, multiple variables need to be considered including a careful risk assessment, the poison's characteristics including toxicokinetics, alternative treatments, the patient's clinical status, and intricacies of available ECTRs, all of which are reviewed in this article. Recently, evidence-based and expert opinion-based recommendations from the EXTRIP workgroup were also published to help minimize the knowledge gap in this area. Here, we will present current systematic reviews and guidelines from the EXTRIP (EXtracorporeal TReatments In Poisonings) workgroup where we discuss potential cardiotoxic drugs such as Digoxin, Tricyclic antidepressants, Carbamazepine.